AG
INSY

Advisor Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Advisor Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,258
Closed -$28K – 5509
2019
Q1 		$28K Sell
6,258
-2,502
-29% -$11.8K ﹤0.01% 3797
2018
Q4 		$31K Hold
8,760
– – ﹤0.01% 3521
2018
Q3 		$89K Buy
8,760
+4,997
+133% +$39.9K ﹤0.01% 2843
2018
Q2 		$28K Hold
3,763
– – ﹤0.01% 3515
2018
Q1 		$23K Buy
3,763
+1,709
+83% +$14.1K ﹤0.01% 3618
2017
Q4 		$20K Sell
2,054
-10
-0.5% -$65 ﹤0.01% 3734
2017
Q3 		$19K Sell
2,064
-290
-12% -$2.99K ﹤0.01% 3597
2017
Q2 		$29K Sell
2,354
-46
-2% -$544 ﹤0.01% 3246
2017
Q1 		$25K Buy
2,400
+729
+44% +$7.77K ﹤0.01% 3241
2016
Q4 		$16K Buy
1,671
+1,171
+234% +$13.2K ﹤0.01% 3378
2016
Q3 		$6K Buy
+500
New +$7.6K ﹤0.01% 3847

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Advisor Group's INSY Position: Q2 2019 in Review

Advisor Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 6,258 shares — an estimated $28K sold.

Advisor Group first reported a position in INSY in Q3 2016 and held it in 11 quarters. The position peaked at $89K in Q3 2018. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Advisor Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 6,258 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $28K.
  • Advisor Group first reported a position in Insys Therapeutics, Inc. in Q3 2016 and held it in 11 quarters.
  • Advisor Group's Insys Therapeutics, Inc. position peaked at $89K in Q3 2018.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.